172617-84-4

Usage

Uses

Used in Pharmaceutical Industry:
N'-DesMethyl AzithroMycin is used as an anti-infective agent for treating various bacterial infections. Its ability to inhibit bacterial growth makes it a valuable component in the development of new antibiotics.
N'-DesMethyl AzithroMycin is also used as an anti-proliferative agent in the field of oncology. It has the potential to inhibit the growth and proliferation of cancer cells, making it a promising candidate for cancer treatment.
In addition, N'-DesMethyl AzithroMycin is used as an anti-inflammatory agent. Its ability to reduce inflammation can be beneficial in treating conditions characterized by excessive inflammation, such as autoimmune disorders and chronic inflammatory diseases.
Furthermore, N'-DesMethyl AzithroMycin is used as a prokinetic agent in the field of gastroenterology. It can help stimulate gastrointestinal motility, which can be useful in treating conditions related to impaired gut movement, such as gastroparesis and constipation.
Overall, N'-DesMethyl AzithroMycin is a versatile compound with potential applications in various areas of medicine, including infectious diseases, oncology, inflammation, and gastrointestinal disorders. Its chemical properties and multifaceted uses make it an important compound for further research and development in the pharmaceutical industry.

Upstream product

• 83905-01-5 Zithromax(R) 
• 90503-06-3 azithromycin-3'-N-oxide 

Downstream Products

• 612069-27-9 3'-N,N-didemethyl-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A 
• 677726-24-8 C₄₁H₇₄N₂O₁₂ 
• 1307759-43-8 3'-N-(benzylthiocarbamoyl)-3'-N-demethyl-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A 
• 957063-17-1 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-[benzyl(methyl)amino]-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one 
• 612069-31-5 N-[(2S,3R,4S,6R)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydropyran-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-3-hydroxy-6-methyltetrahydropyran-4-yl]-N,4-dimethylbenzenesulfonamide 
• 1236116-85-0 C₄₄H₇₅N₃O₁₄ 
• 1236116-08-7 N-3'-p-bromobenzyl-N-3'-desmethylazithromycin 
• 1093856-81-5 (3'-N-(4-ethynylbenzyl))azithromycin 
• 1093857-05-6 C₅₃H₉₁N₃O₁₅ 
• 957063-68-2 3'-N-demethyl-3'-N-benzyloxycarbonyl-9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A 
• 864527-72-0 C₄₇H₇₇N₃O₁₄ 

Relevant academic research and scientific papers

ANTI-INFECTIVE AND ANTI-VIRAL COMPOUNDS AND COMPOSITIONS

Lysosomally accumulated substances that release a nitroxy group, or a short chain fatty acid or a product of anaerobic metabolism or a thiol or a sulfide often from an ester or similar labile linkage have anti-inflammatory, anti-cancer and anti-bacterial activity. They are useful in treating infectious, inflammatory and malignant disease and are immune stimulatory, promote zinc uptake, disable endosomal reactions and synergise anti-viral action of protease inhibitors. The compounds are useful for the treatment of bacterial, viral and mixed pneumonias.

TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME

The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.

NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS

Lysosomally accumulated substances that release a nitroxy group, or a short chain fatty acid or a product of anaerobic metabolism or a thiol or a sulfide often from an ester or similar labile linkage have anti-inflammatory, anti-cancer and anti-bacterial activity. They are useful in treating infectious, inflammatory and malignant disease.

KINASE MODULATORS FOR THE TREATMENT OF CANCER

A method of treating cancer in which a compound that inhibits the expression, production or release of IL-10 by immune cells is combined with a compound that stimulates the production of IL-12 when given in combination with, or in the presence of TNFa. Sa

Macrocyclic lactone impurity synthetic method

The invention relates to a method for preparing an azithromycin impurity I and an azithromycin impurity E. The method comprises the following steps: mixing azithromycin with a solvent, and adding the mixture into a compound which is shown as (I) in the description to perform a demethylation reaction, wherein R1 and R2 are respectively and independently methyl, ethyl, propyl, naphthenic group, a phenyl and p-methylphenyl. According to the method for preparing azithromycin impurity, the reaction is carried out under a mild condition; the method can be used for preparing the azithromycin impurity I and the azithromycin impurity E by controlling the amount of a reagent; the HPLC purity of the azithromycin impurities prepared by the method is 98 percent or more.

Novel hybrid molecules based on 15-membered azalide as potential antimalarial agents

Malaria remains the most prevalent tropical disease, and due to the spread of resistant parasites novel therapeutics are urgently needed. Azithromycin has shown potential in malaria treatment so we designed hybrid azalide molecules with the aim to improve activity against and selectivity for the malaria parasite. Novel hybrid molecules comprising 4-aminoquinoline moiety covalently liked to 15-membered azalide scaffold at position C-3′ were synthesized and biologically evaluated. Antimalarial testing against Plasmodium falciparum sensitive and resistant strains confirmed the improved in vitro activity over azithromycin and chloroquine. Selectivity of the compounds (HepG2 IC 50/P. falciparum IC50 ratio) for the parasite was high (100-2700) and their antibacterial activity diminished. Even though oral bioavailability determined for compound 12 was low, novel quinoline C-3′-substituted 15-membered azalides represent an interesting subclass of antimalarial macrolides that need further research and evaluation.

Novel desosamine-modified 14- and 15-membered macrolides without antibacterial activity

Novel modifications of the desosamine sugar of 14- and 15-membered antibacterial macrolides, in which the desosamine was fused with N-substituted-1,3-oxazolidin-2-ones, were developed in order to completely suppress antibacterial activity and make them pr

N-Substituted-2′-O,3′-N-carbonimidoyl bridged macrolides: Novel anti-inflammatory macrolides without antimicrobial activity

Macrolide antibiotics, like erythromycin, clarithromycin, and azithromycin, possess anti-inflammatory properties. These properties are considered fundamental to the efficacy of these three macrolides in the treatment of chronic inflammatory diseases like diffuse panbronchiolitis and cystic fibrosis. However, long-term treatment with macrolide antibiotics presents a considerable risk for promotion of bacterial resistance. We have examined antibacterial and anti-inflammatory effects of a novel macrolide class: N-substituted 2′-O,3′-N-carbonimidoyl bridged erythromycin-derived 14- and 15-membered macrolides. A small focused library was prepared, and compounds without antimicrobial activity, which inhibited IL-6 production, were selected. Data analysis led to a statistical model that could be used for the design of novel anti-inflammatory macrolides. The most promising compound from this library retained the anti-inflammatory activity observed with azithromycin in lipopolysaccharide-induced pulmonary neutrophilia in vivo. Importantly, this study strongly suggests that antimicrobial and anti-inflammatory activities of macrolides are independent and can be separated, which raises development plausibility of novel anti-inflammatory therapeutics.

Novel tandem reaction for the synthesis of Na′-substituted 2-imino-1,3-oxazolidines from vicinal (sec- or tert-)amino alcohol of desosamine

Two one-pot methods, sequential and tandem, for the preparation of Na′-substituted 2-imino-1,3-oxazolidines from the vicinal (sec- or tert)-amino alcohol of desosamine via intermediary alkyl-, aryl-, heteroaryl-, and heteroalkyl-thiourea moieties are described. Particularly interesting is the novel one-pot tandem reaction of the vicinal tert-amino alcohol that involves dealkylation, thiourea formation, and a final cyclization to yield 2-imino-1,3-oxazolidine structures. The yields of both one-pot methods are comparable to the yield of the sequential reaction. A small library of a new class of desosamine-modified 14- and 15-membered macrolides was prepared to demonstrate the variety of substituents that can be easily introduced and thus enable a huge variation of the physicochemical and hence biological properties of these new molecules. Na′-Substituted 2-imino-1,3-oxazolidines have been condensed onto a desosamine amino sugar by two one-pot methods. A novel one-pot tandem reaction of the 2a′,3a′-vicinal tert-amino alcohol of desosamineinvolving dealkylation, thiourea formation, and a final cyclization to yield 2-imino-1,3-oxazolidine structures with a Z configuration around the imine bond has been discovered. Copyright

3'-N-SUBSTITUTED 9-DEOXO-9A-METHYL-9A-AZA-HOMOERYTHROMYCIN HAVING ANTIMALARIAL ACTIVITY

The present invention relates to novel 3'-N-substituted 9-deoxo-9a-methyl-9a-aza-9a- homoerythromycin A derivatives having antimalarial activity. More particularly, the invention relates to 3'-N-substituted-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A and 3'-N-substituted-3-O-decladinosyl-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A derivatives having antimalarial activity, to the intermediates for their preparation, to the methods for their preparation, to their use as therapeutic agents, and to salts thereof having antimalarial activity.